



# Preparing for a Post-COVID World

Growth and value both present opportunities amid the pandemic.

August 2020

## KEY INSIGHTS

- Developed market equity valuations generally appear reasonable given extremely low interest rates but vary widely among sectors and regions.
- The gap between growth and value stocks is almost without precedent, and the rotation back to value—although difficult to time—is likely to be forceful.
- Likewise, the global economy's reliance on unparalleled fiscal and monetary stimulus means tail risks have become elevated.

## Q: Are markets reflecting too optimistic an outlook for the rest of 2020?

As of early August, the MSCI EAFE Index was trading around 18.5 times estimated earnings over the next 12 months—a modestly elevated level that can be justified in the context of very low interest rates. The market also seems to be rational in pricing in a further reopening of the global economy over the next 12 to 18 months. Even as we await a vaccine, treatment protocols for the coronavirus are improving, and a level of herd immunity seems likely to emerge. It also appears inevitable that people will allow themselves to engage in more risky behavior—for good or ill—as they grow fatigued with the shutdowns. Finally, valuations reasonably reflect the massive fiscal and monetary stimulus that has been directed at reviving the global economy.

## Q: What permanent marks do you see COVID-19 leaving on the global economy?

Physical retail seems likely to be permanently impaired, and it is telling that e-commerce continues to grow in Europe even as shops reopen. Business travel will also bear lasting scars, but I expect it will come back to around 80% to 90% of its previous levels once the pandemic is over. People are social animals, and I expect that leisure travel and restaurants will eventually come back very strongly—especially as a wave of pent-up demand is released following the end of the pandemic. We should also see steady growth and progress in the health care sector, which is of course getting a lot of attention right now. We're interested not only in pharmaceutical firms, but also in companies involved in medical services and diagnostics.



**Raymond Mills**

*Portfolio Manager, International Core Equity Strategy*

...there's not going to be plenty of time to shift your portfolio. We think it's important to have some exposure to value now.

**Q: What factors would need to come into play for a sustained value rally?**

The performance gap early in the pandemic between growth and value in international markets was only matched briefly during the financial crisis, and the current differential remains extreme. It is very hard to identify a catalyst for value to rebound, however, partly because technical factors are at play. For example, Japan's central bank is buying exchange-traded funds, which tends to favor stocks that have done relatively well and are heavily weighted in the indexes.

Rising interest rates and inflation could spark a market rotation, but that is not our base case; more likely, it is the continued reopening of the global economy that will eventually favor value. History does suggest that the reversal may be forceful when it comes—which is to say that there's not going to be plenty of time to shift your portfolio. Accordingly, we think it's important to have some exposure to value now.

**Q: Has the massive monetary and fiscal stimulus in response to the pandemic changed how you think about valuation?**

Certainly, risk-free interest rates below zero in many regions make future earnings much more valuable. In that light, it's understandable that investors are bidding up the stocks of companies with healthy and reliable cash flows, such as e-commerce and medical technology firms. What I find more interesting—and a source of opportunity—is that the market is not applying the same discount model to industrial companies, for example, that have more volatility in their cash flows but are still growing at a healthy pace over the long term. In theory, very low rates mean investors should also be favoring stocks with healthy dividend yields, but that is also not the case. This makes some sense, as dividend cuts have been occurring as companies seek to preserve liquidity. That's why we're less interested in stocks with a high dividend yield—often

a sign of distress—than in companies that are able to grow their dividends.

**Q: Where are you seeing opportunities from a regional or sectoral perspective?**

The U.S. market is expensive relative to the rest of the world, which can be justified given its higher weighting in technology stocks and higher return on equity. But the valuation gap seems extreme, with stocks much pricier in the U.S. on sales and book value, in particular. Valuation differentials across sectors are still somewhat extreme—as, for example, with consumer staples versus financials. And, finally, there is the substantial gap between growth and value names within sectors. This is particularly true in health care, where we're seeing opportunities in stocks that have been left behind in the momentum-driven rally.

**Q: How are U.S.-China tensions affecting your outlook?**

The tensions with China are based on real issues surrounding technology and international competition, and you can make an argument that they might even increase under a Biden administration. We limit our direct exposure to China, partly because we are primarily focused on developed markets. We are also being careful to avoid companies involved in sensitive activities, such as technologies that enable surveillance.

At the same time, China is a huge market that offers real potential for investors, and we are invested in some leading internet companies as well as a couple of insurance firms. Recently, the prospect of Chinese companies being delisted from U.S. stock exchanges has gathered some attention, but that doesn't really concern us. I expect they'll just move instead to Hong Kong, which should not result in any substantial value destruction for investors. It's also notable that emerging trade barriers with China are creating some opportunities for

## Global Equity Valuations

(Fig. 1) Non-U.S. stocks are cheaper relative to history

	Price/Earnings		Price/Book		Return on Equity		Dividend Yield	
	Current	Median	Current	Median	Current	Median	Current	Median
<b>S&amp;P 500 Index</b>	21.7	14.4	3.5	2.7	15.6%	15.2%	1.9%	1.9%
<b>MSCI EAFE Index</b>	17.1	13.6	1.5	1.6	9.7%	10.1%	2.8%	3.1%

As of June 30, 2020

Median data points are for the trailing 15 years.

Sources: Standard & Poor's, MSCI (see Additional Disclosures). T. Rowe Price analysis using data from FactSet Research Systems Inc. All rights reserved.

outside firms—as with European firms poised to seize 5G telecom equipment markets away from Chinese giant Huawei.

### Q: What are the main risks you see for the market?

Investors do not seem to appreciate the global economy's reliance on fiscal and monetary stimulus. Global central banks poured USD 4 trillion into the global financial system in March and have added more since. The U.S. alone

is expected to run a deficit this year that is roughly equivalent to one-fifth of gross domestic product. While this extreme level of support may have been necessary, it's clearly not sustainable. How and when the withdrawal of this underpinning will play out is highly uncertain, and history can offer a lot of different scenarios. But it's clear that we've moved further out on the limb, so to speak.

The specific securities identified and described are for informational purposes only and do not represent recommendations.

### Additional Disclosures

Source: MSCI. MSCI and its affiliates and third party sources and providers (collectively, "MSCI") makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indices or any securities or financial products. This report is not approved, reviewed, or produced by MSCI. Historical MSCI data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. None of the MSCI data is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.

## INVEST WITH CONFIDENCE<sup>SM</sup>

T. Rowe Price focuses on delivering investment management excellence that investors can rely on—now and over the long term.

# T. Rowe Price<sup>®</sup>

### Important Information

**This material is being furnished for general informational and/or marketing purposes only.** The material does not constitute or undertake to give advice of any nature, including fiduciary investment advice, nor is it intended to serve as the primary basis for an investment decision. Prospective investors are recommended to seek independent legal, financial and tax advice before making any investment decision. T. Rowe Price group of companies including T. Rowe Price Associates, Inc. and/or its affiliates receive revenue from T. Rowe Price investment products and services. **Past performance is not a reliable indicator of future performance.** The value of an investment and any income from it can go down as well as up. Investors may get back less than the amount invested.

The material does not constitute a distribution, an offer, an invitation, a personal or general recommendation or solicitation to sell or buy any securities in any jurisdiction or to conduct any particular investment activity. The material has not been reviewed by any regulatory authority in any jurisdiction.

Information and opinions presented have been obtained or derived from sources believed to be reliable and current; however, we cannot guarantee the sources' accuracy or completeness. There is no guarantee that any forecasts made will come to pass. The views contained herein are as of the date written and are subject to change without notice; these views may differ from those of other T. Rowe Price group companies and/or associates. Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price.

The material is not intended for use by persons in jurisdictions which prohibit or restrict the distribution of the material and in certain countries the material is provided upon specific request. It is not intended for distribution to retail investors in any jurisdiction.

**Australia**—Issued in Australia by T. Rowe Price Australia Limited (ABN: 13 620 668 895 and AFSL: 503741), Level 50, Governor Phillip Tower, 1 Farrer Place, Suite 50B, Sydney, NSW 2000, Australia. For Wholesale Clients only.

**Canada**—Issued in Canada by T. Rowe Price (Canada), Inc. T. Rowe Price (Canada), Inc.'s investment management services are only available to Accredited Investors as defined under National Instrument 45-106. T. Rowe Price (Canada), Inc. enters into written delegation agreements with affiliates to provide investment management services.

**DIFC**—Issued in the Dubai International Financial Centre by T. Rowe Price International Ltd. This material is communicated on behalf of T. Rowe Price International Ltd. by its representative office which is regulated by the Dubai Financial Services Authority. For Professional Clients only.

**EEA ex-UK**—Unless indicated otherwise this material is issued and approved by T. Rowe Price (Luxembourg) Management S.à r.l. 35 Boulevard du Prince Henri L-1724 Luxembourg which is authorised and regulated by the Luxembourg Commission de Surveillance du Secteur Financier. For Professional Clients only.

**Hong Kong**—Issued by T. Rowe Price Hong Kong Limited, 6/F, Chater House, 8 Connaught Road Central, Hong Kong. T. Rowe Price Hong Kong Limited is licensed and regulated by the Securities & Futures Commission. For Professional Investors only.

**New Zealand**—Issued in New Zealand by T. Rowe Price Australia Limited (ABN: 13 620 668 895 and AFSL: 503741), Level 50, Governor Phillip Tower, 1 Farrer Place, Suite 50B, Sydney, NSW 2000, Australia. No Interests are offered to the public. Accordingly, the Interests may not, directly or indirectly, be offered, sold or delivered in New Zealand, nor may any offering document or advertisement in relation to any offer of the Interests be distributed in New Zealand, other than in circumstances where there is no contravention of the Financial Markets Conduct Act 2013.

**Singapore**—Issued in Singapore by T. Rowe Price Singapore Private Ltd., No. 501 Orchard Rd, #10-02 Wheelock Place, Singapore 238880. T. Rowe Price Singapore Private Ltd. is licensed and regulated by the Monetary Authority of Singapore. For Institutional and Accredited Investors only.

**Switzerland**—Issued in Switzerland by T. Rowe Price (Switzerland) GmbH, Talstrasse 65, 6th Floor, 8001 Zurich, Switzerland. For Qualified Investors only.

**UK**—This material is issued and approved by T. Rowe Price International Ltd, 60 Queen Victoria Street, London, EC4N 4TZ which is authorised and regulated by the UK Financial Conduct Authority. For Professional Clients only.

**USA**—Issued in the USA by T. Rowe Price Associates, Inc., 100 East Pratt Street, Baltimore, MD, 21202, which is regulated by the U.S. Securities and Exchange Commission. For Institutional Investors only.

© 2020 T. Rowe Price. All rights reserved. T. ROWE PRICE, INVEST WITH CONFIDENCE, and the bighorn sheep design are, collectively and/or apart, trademarks or registered trademarks of T. Rowe Price Group, Inc.